Auranofin Capsules (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Therefore, the results of recommended laboratory work (See PRECAUTIONS) should be reviewed before writing each Auranofin Capsules prescription. Like other gold preparations, Auranofin Capsules is only indicated for use in selected patients with active rheumatoid arthritis. Physicians planning to use Auranofin Capsules should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of Auranofin Capsules.

In addition, the following precautions should be routinely employed:

1. The possibility of adverse reactions should be explained to patients before starting therapy.

2. Patients should be advised to report promptly any symptoms suggesting toxicity. (See PRECAUTIONS -- Information for Patients).